In comparing t-AML and de novo AML with favorable cytogenetics, Aldoss and Pullarkat concluded that a history of prior cytotoxic treatment can affect outcome in CBF AML but not to the degree of advocating a change in treatment strategy or transplantation indications for CBF t-AML. Here, CEBPZ is linked to acute myeloid leukemia.